Ranbaxy Chairman Says No Change To Lipitor Generic Launch Timeline In U.S.; Dismisses Speculation Of $1 Bn FDA Penalty
By
Pharmasia News / PharmAsia News Sep. 8, 2011 1:00 PM GMT
India / Word Count: 758 / Article # 28110908003
Executive Summary
MUMBAI - Share prices of Ranbaxy Laboratories Ltd. rose nearly 5% on an otherwise flat day of trading at the Bombay Stock Exchange backed by news that the company is "on schedule" to launch generic versions of Lipitor (atorvastatin) in the United States
$50.00
Buy Now
For $50.00, purchase this 758-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.